Help us: Donate
Follow us on:

Using a Natural Antibody to Combat Atherosclerosis


Researchers at the University of California San Diego School of Medicine have shown that they can block inflammation in mice, thereby protecting them from liver disease and hardening of the arteries while increasing their healthy lifespan.

The study, published in the journal Nature, shows that inflammation can be blocked using a naturally occurring antibody that binds with oxidized phospholipids (OxPL), molecules that are located on the cell surface and are modified by inflammation [1]. This is the first time in a living animal that OxPL has been shown to trigger inflammation that leads to the formation of arterial plaques, the foundation of heart disease.

The mice were given a high-fat diet and treated with the antibody, which prevented artery-hardening arterial plaques from forming, prevented liver disease, and increased their lifespan. The study results also highlight a potential new approach to preventing or reversing a variety of inflammatory diseases.

The researchers observed that whenever there is inflammation, there is OxPL. While this fact does not suggest that OxPL is the cause, the researchers knew that it has an important role in that process and the resulting diseases. Phospholipids are molecules that form the cell membrane, and they are prone to modification from reactive oxygen species, thus forming OxPL. This happens in inflammatory diseases such as atherosclerosis, in which plaques form and block the arteries, leading to heart attack and stroke.

For a disease model, the research team created specially engineered mice with a genetic mutation that made them prone to atherosclerosis. They also generated a piece of a naturally occurring antibody called E06 that could bind to OxPL and prevent it from causing inflammation in immune cells. They then gave the mice a high-fat diet, which is generally enough to encourage them to develop atherosclerosis due to their genetic mutation.

Compared to the control mice, the E06 antibody-producing mice had between 28-57 percent less atherosclerotic plaque, even a year later, while having high cholesterol. The antibody also reduced the hardening and narrowing of the aortic valves, fatty liver disease, and inflammation in the liver. The E06 mice also showed a 32 percent reduction in serum amyloid A, a biomarker of systemic inflammation.

Finally, the E06 mice lived longer than their control counterparts. After a 15-month period, all of the E06 mice were still alive, while only 54 percent of the control mice were.

The study shows for the first time that OxPL is pro-inflammatory, plays a major role in the development of atherosclerosis, and, most importantly, can be countered using the E06 antibody. This suggests that therapies that reduce the activity of OxPL could prove useful in reducing inflammation while helping to combat atherosclerosis and similar diseases. The researchers are now testing the E06 antibody in mouse models of other inflammatory diseases, including osteoporosis and nonalcoholic liver disease.


The effective control of pro-inflammatory processes that encourage the development of atherosclerosis is very welcome news. Should these researchers successfully develop an E06 antibody therapy for people, it may be a solution to combating heart disease.

This is one of a number of approaches currently being explored by researchers to address atherosclerosis, so hopefully, we may have more effective methods in the near future.


[1] Que, X., Yeang, C., Hung, M. Y., Yamaguchi, F., Diehl, C. J., Gonen, A., … & Mellon, P. L. (2016). Oxidized Phospholipids Are Proinflammatory and Proatherogenic.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.